PE20221572A1 - Formulaciones de farmacos polibasicos para reducir la toxicidad multiorganica - Google Patents
Formulaciones de farmacos polibasicos para reducir la toxicidad multiorganicaInfo
- Publication number
- PE20221572A1 PE20221572A1 PE2022001099A PE2022001099A PE20221572A1 PE 20221572 A1 PE20221572 A1 PE 20221572A1 PE 2022001099 A PE2022001099 A PE 2022001099A PE 2022001099 A PE2022001099 A PE 2022001099A PE 20221572 A1 PE20221572 A1 PE 20221572A1
- Authority
- PE
- Peru
- Prior art keywords
- cationic
- macromolecule
- molecular weight
- group
- polybasic
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000001988 toxicity Effects 0.000 title abstract 2
- 231100000419 toxicity Toxicity 0.000 title abstract 2
- 125000002091 cationic group Chemical group 0.000 abstract 4
- 229920002307 Dextran Polymers 0.000 abstract 3
- 229920002521 macromolecule Polymers 0.000 abstract 3
- 150000001413 amino acids Chemical class 0.000 abstract 2
- -1 dextran Chemical class 0.000 abstract 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 1
- 229920001661 Chitosan Polymers 0.000 abstract 1
- 229920001353 Dextrin Polymers 0.000 abstract 1
- 239000004375 Dextrin Substances 0.000 abstract 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 abstract 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 108010040201 Polymyxins Proteins 0.000 abstract 1
- 229920001218 Pullulan Polymers 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000001767 cationic compounds Chemical class 0.000 abstract 1
- 238000010382 chemical cross-linking Methods 0.000 abstract 1
- 238000007385 chemical modification Methods 0.000 abstract 1
- 229940045110 chitosan Drugs 0.000 abstract 1
- 235000019425 dextrin Nutrition 0.000 abstract 1
- 230000009881 electrostatic interaction Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 229920000669 heparin Polymers 0.000 abstract 1
- 229960002897 heparin Drugs 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 229920002674 hyaluronan Polymers 0.000 abstract 1
- 229960003160 hyaluronic acid Drugs 0.000 abstract 1
- 229940041153 polymyxins Drugs 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
- 235000019423 pullulan Nutrition 0.000 abstract 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/721—Dextrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composiciones y formulaciones elaborados de farmacos polibasicos para reducir las toxicidades multiorganicas en los mamiferos, mediante la formacion de complejos cationicos supramoleculares sin reticulacion quimica ni covalentes, en donde dichos complejos comprenden: (a) un farmaco polibasico/cationico seleccionado entre un grupo de antibioticos aminoglucosidos o polimixinas; (b) un compuesto cationico seleccionado del grupo de las aminas etoxiladas, compuestos de amonio cuaternario, aminoacidos en donde dicho aminoacido se selecciona de entre la l-arginina, la l-lisina y la histidina; (c) una macromolecula para la base del andamio; en donde dicha macromolecula se selecciona de un grupo de polisacaridos naturales como el dextrano, el acido polisialico, los pululanos, la dextrina, el acido hialuronico, el quitosano y la heparina, en donde dicha macromolecula es un dextrano de bajo peso molecular sin modificacion quimica; en donde dicho complejo se forma por interacciones electrostaticas cationicas en relacion de peso molecular de carga especificada; en donde la proporcion de dicho farmaco cationico: aminoacido cationico: dextrano de bajo peso molecular es de 1:0.1: 0.1 a 1: 3: 1; (d) en donde dicho complejo se administra a un sujeto que lo necesita por via parenteral.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201911051914 | 2019-12-14 | ||
| PCT/IN2020/051027 WO2021117065A1 (en) | 2019-12-14 | 2020-12-13 | Formulations of polybasic drugs to reduce multi-organ toxicity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20221572A1 true PE20221572A1 (es) | 2022-10-06 |
Family
ID=76329703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022001099A PE20221572A1 (es) | 2019-12-14 | 2020-12-13 | Formulaciones de farmacos polibasicos para reducir la toxicidad multiorganica |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230104323A1 (es) |
| EP (1) | EP4072563A4 (es) |
| JP (1) | JP2023516848A (es) |
| CN (1) | CN115003311B (es) |
| BR (1) | BR112022011800A2 (es) |
| CA (1) | CA3164789A1 (es) |
| CO (1) | CO2022009909A2 (es) |
| IL (1) | IL293883A (es) |
| JO (1) | JOP20220144A1 (es) |
| MX (1) | MX2022007292A (es) |
| PE (1) | PE20221572A1 (es) |
| WO (1) | WO2021117065A1 (es) |
| ZA (1) | ZA202207816B (es) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6275800A (en) * | 1999-07-16 | 2001-02-05 | Mallinckrodt, Inc. | Inhibition of renal uptake of molecules that are potentially damaging for the kidney |
| FI20010764A0 (fi) * | 2001-04-11 | 2001-04-11 | Map Medical Technologies Oy | Kationiset dekstraanijohdannaiset käytettäväksi munuaisten suojaamiseen |
| AU2002307802A1 (en) * | 2002-04-25 | 2003-10-08 | Recepticon Aps | Antagonists of megalin or cubilin for use in preventing organ damage induced by therapeutic agents |
| JP2006520761A (ja) * | 2003-03-26 | 2006-09-14 | レセプトイコン・アンパルトセルスカブ | 薬物誘発性細胞毒性の予防のための化合物の使用 |
| KR20110058887A (ko) * | 2008-09-18 | 2011-06-01 | 마누 차우드하리 | 신규한 단일 유닛 카바페넴 아미노글라이코사이드 제형 |
| EP2475358B1 (en) * | 2009-09-09 | 2019-06-05 | Pharmain Corporation | Anionic-core composition for delivery of therapeutic agents, and methods of making and using the same |
| US10953070B2 (en) * | 2014-07-25 | 2021-03-23 | Agency For Science, Technology And Research | Antibiotic compositions for treating bacterial infections |
| CA3040795A1 (en) * | 2016-10-21 | 2018-04-26 | Algipharma As | Polymyxin-alginate oligomer conjugates |
-
2020
- 2020-12-13 BR BR112022011800A patent/BR112022011800A2/pt unknown
- 2020-12-13 EP EP20899512.6A patent/EP4072563A4/en active Pending
- 2020-12-13 IL IL293883A patent/IL293883A/en unknown
- 2020-12-13 CN CN202080094644.5A patent/CN115003311B/zh active Active
- 2020-12-13 MX MX2022007292A patent/MX2022007292A/es unknown
- 2020-12-13 WO PCT/IN2020/051027 patent/WO2021117065A1/en active Application Filing
- 2020-12-13 US US17/785,100 patent/US20230104323A1/en active Pending
- 2020-12-13 CA CA3164789A patent/CA3164789A1/en active Pending
- 2020-12-13 JP JP2022536594A patent/JP2023516848A/ja active Pending
- 2020-12-13 JO JOP/2022/0144A patent/JOP20220144A1/ar unknown
- 2020-12-13 PE PE2022001099A patent/PE20221572A1/es unknown
-
2022
- 2022-07-13 ZA ZA2022/07816A patent/ZA202207816B/en unknown
- 2022-07-14 CO CONC2022/0009909A patent/CO2022009909A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022007292A (es) | 2022-11-14 |
| ZA202207816B (en) | 2023-03-29 |
| CO2022009909A2 (es) | 2022-07-19 |
| CN115003311A (zh) | 2022-09-02 |
| EP4072563A1 (en) | 2022-10-19 |
| CN115003311B (zh) | 2024-04-19 |
| EP4072563A4 (en) | 2024-01-24 |
| JP2023516848A (ja) | 2023-04-21 |
| CA3164789A1 (en) | 2021-06-17 |
| US20230104323A1 (en) | 2023-04-06 |
| BR112022011800A2 (pt) | 2022-08-30 |
| WO2021117065A1 (en) | 2021-06-17 |
| JOP20220144A1 (ar) | 2023-01-30 |
| IL293883A (en) | 2022-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122226T1 (el) | Προφαρμακα που περiλαμβανουν συζευγμα εξενδινης αρθρωτη | |
| AR115885A1 (es) | Compuestos derivados de 1h-pirazolo[4,3-d]pirimidina como agonistas del receptor 7 tipo toll (tlr7) y su uso en combinación con un agente de inmunoterapia anticancerígeno | |
| US20190240288A1 (en) | Nanocomplexes for delivery of saporin | |
| ECSP20021913A (es) | Moduladores de la proteína reguladora de conductancia transmembrana de la fibrosis quística y métodos de uso | |
| AR112414A1 (es) | Agonistas del receptor tipo toll 7 (tlr7) que tienen una porción benzotriazol, conjugados de estos y métodos y usos de estos | |
| MA42232B1 (fr) | Nouveaux dérivés d'acide aminé, leur procédé de préparation et compositions pharmaceutiques les contenant | |
| AR095366A1 (es) | Poliamidas funcionales de amina | |
| AR107864A1 (es) | ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS | |
| AR079752A1 (es) | Prodrogas de sales de amonio cuaternario | |
| AR075447A1 (es) | Sales y polimorfos de un compuesto de tetraciclina, metodo de obtencion y composiciones farmaceuticas | |
| AR110299A1 (es) | Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico | |
| JP2015514826A5 (es) | ||
| CY1124782T1 (el) | Φαρμακοτεχνικες μορφες μακρας δρασης | |
| ES2859923T3 (es) | Compuestos de disulfuro para el suministro de agentes farmacéuticos | |
| ECSP21035414A (es) | Conjugados de fármaco-anticuerpo | |
| PE20221572A1 (es) | Formulaciones de farmacos polibasicos para reducir la toxicidad multiorganica | |
| CL2022000893A1 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
| MA45748A (fr) | Conjugués d'acide hyaluronique et de composés anticancéreux. | |
| AR101060A1 (es) | Conjugados de fviii | |
| RU2017104223A (ru) | Полиамины с определенной главной цепью | |
| PE20231948A1 (es) | Compuestos aromaticos que contienen boro y analogos de insulina | |
| RU2012102319A (ru) | Новые противовирусные соединения, подходящие для лечения или предотвращения эпидемического кератоконъюнктивита | |
| PH12018501373A1 (en) | Novel phosphinane and azaphosphinane derivatives, method for preparing same and pharmaceutical compositions containing same | |
| WO2020021489A3 (en) | Discovery of novel first in class nature-inspired compounds targeting the mitochondrial function and pharmaceutical composition thereof | |
| RU2013119012A (ru) | Полиуретановая композиция для покрытий |